The Future is Equal

Archives for November 21, 2022

Just a quarter of Pfizer’s COVID-19 treatment orders will go to developing countries

Some nations could be paying ten times the price of Paxlovid’s generic equivalent, as WHO chief calls for treatment access to battle acute and long COVID-19

Rich countries have secured almost three times as many courses of a World Health Organisation (WHO)-recommended COVID-19 medicine, Pfizer’s Paxlovid, according to new analysis from Oxfam and the People’s Vaccine Alliance.

Using new data from Airfinity, they found that just a quarter of orders for the treatment will go to low- and middle-income countries, despite the fact they make up 84 per cent of the world’s population and have a much greater need as far fewer people are vaccinated against COVID, unlike rich nations which are largely protected.

On the eve of crunch talks at the World Trade Organisation (WTO) over intellectual property rules for COVID-19 treatments and tests, the organisations are warning that we are seeing the same worrying trend of inequity that we saw with COVID vaccines.

Pfizer’s monopoly also means that some middle-income countries could be paying ten times more for Paxlovid than a generic equivalent, with reports of them being quoted as much as US$250 per course. This is despite the fact that other lower-income countries will have access to a Clinton Health Initiative (CHAI) deal with Pfizer and undisclosed generic companies, which means they could access the treatment for just US$25 a course. 

Dr. Catherine Kobutungi, Executive Director of the African Population and Health Research Center said: “When vaccines were our main medical tool to fight COVID-19, big pharmaceutical companies prioritized maximizing their profits by selling doses to the richest countries. Millions died while people in low- and middle-income countries were sent to the back of the vaccine queue. And now, we are witnessing a repetition of the same inequity with COVID-19 treatments and tests.”

“Oral antiviral treatments are easy to administer. They reduce hospitalisation and cut deaths. And they may reduce the likelihood of long COVID. Yet, right now, they’re nearly exclusively accessible to people in the richest countries. The fact is that if you are a vulnerable person with COVID-19 in a high-income country, you will probably have access to treatments that can help you survive. If you live in a lower-income country, you probably won’t. It’s grotesque inequality and it kills”, she added.

The WHO recommends using Paxlovid to cut COVID-19 hospitalisation and death rates, and has called for equitable global access to COVID-19 medicines as part of a strategy to combat long COVID. A recent, non-reviewed study suggests that Paxlovid may lower the risk of patients developing long COVID.

There are hundreds of other potential COVID-19 medicines in the development pipeline, including at least 77 in late-stage clinical trials that could be more effective and have a wider scope of use. However, intellectual property rules are giving a small number of companies a monopoly on supply, allocation, and price, meaning low- and middle-income countries are unlikely to have affordable access to these medicines either.

Because far fewer people in low-income countries are vaccinated than in rich countries, they are more vulnerable to hospitalisation and death from COVID-19. These countries have already experienced the highest death toll in the pandemic, a trend that could continue without access to treatments like Paxlovid.

Jennifer Reid, Senior Health and Vaccine Equity Advisor at Oxfam, said: “After the inequity they faced with the vaccine rollout, developing countries are now experiencing access and affordability issues for COVID treatments. It is a disgrace that those who need them the most are receiving the least and that patent laws are handing Pfizer a long monopoly on this lifesaving medicine. 

“Addressing both acute and long COVID is essential – and the WHO has been clear that countries need treatments like Paxlovid to cut deaths and hospitalisations. But the patents minefield is a massive barrier preventing many developing countries from getting the medicines and tests they need now and in the future to save lives.”

In June, after a year and a half of negotiations, the WTO rejected proposals to waive intellectual property rules for all COVID-19 medical technologies, adopting a far more limited text that only covers vaccines. Ahead of talks taking place tomorrow in Geneva, civil society organizations are urging WTO member states to immediately agree to an extension to include treatments and tests, which would allow developing countries to produce for their own populations and export for others in need, ensuring essential tools are accessible and affordable.

Mohga Kamal Yanni, Policy Co-Lead for the People’s Vaccine Alliance, said: “Decades ago, governments allowed pharmaceutical companies to control the price, allocation, and supply of lifesaving HIV medicines – and millions of people died without affordable access. Now, the same thing is happening again with COVID-19 vaccines and medicines. Companies have been allowed to decide who lives and who dies. WTO member states must ensure that public health takes precedence over commercial interest.”


Notes to editors

A new briefing note from the People’s Vaccine Alliance on the case for the extension of the WTO ministerial decision to therapeutics and diagnostics is available here.

Data from Airfinity shows that the richest countries who account for just 16 per cent of the world’s population will receive 74 per cent of all courses ordered of Paxlovid. Low- and middle-income countries who make up 84 per cent of the world’s population will receive just 26 per cent. Despite being first authorised in December 2021, reports suggest that few doses are available to people in low and middle-income countries.

While there is little data available on how many doses of Pfizer’s antiviral treatment have actually been delivered to low and middle-income countries, they have been waiting for months to receive doses through Paxlovid supply agreements from global initiatives like UNICEF and the Global Fund. Pfizer has allegedly insisted that the prices in these agreements remain secret, and the initiatives have not revealed the prices Pfizer charges for courses through their agreements.

Allocation to high-income vs low- and middle-income countries

Proportion of agreed allocation to high-income vs low- and middle-income countries

Source: Airfinity, a life sciences analytics company


High-income countries (%)

Low- and middle-income countries (%)

Pfizer: Ritonavir-Boosted Nirmatrelvir (Paxlovid)








Data note: These figures reflect deals agreed with Pfizer. There are a number of generic manufacturers expected to produce Paxlovid that have signed agreements through the Medicines Patent Pool. However, these agreements are not expected to be producing/exporting finished drug products at scale until early 2023.

According to the World Intellectual Property Organization (WIPO), there are at least 1,465 patents on treatments and 417 on vaccines for COVID-19:

Loss and damage fund at COP27 a monumental win, if properly funded

Responding to the final communiqué of the COP27 climate talks in Sharm El-Sheikh, Gabriela Bucher, Oxfam International’s Executive Director, said:

“The establishment of a loss and damage fund is a monumental achievement for vulnerable developing countries and communities at the frontlines of the climate crisis. They have been calling for funding to cope with the devastating impacts of climate change for over 30 years.

“Given the urgency on the ground, the fund must be operationalised as soon as possible. Rich countries largely responsible for warming our planet should immediately mobilise substantial new and additional resources to pay for climate-related damage in vulnerable countries.

“In East Africa, nearly 40 million people are experiencing climate-induced hunger. Recent catastrophic floods in Pakistan have inflicted more than US$30 billion in damages and economic losses and left 10 to 12 percent of the country’s land area under water, affecting more than 33 million people. The list of extreme weather events and disasters is growing, as are the devastating impacts on communities.

“While we applaud the establishment of the loss and damage fund, we remain deeply concerned about countries’ failure to agree on an equitable and urgent phase-out of all fossil fuels. The world is on track for a catastrophic 2.8°C of warming.

“Rich countries, especially the US and those in the EU, have failed to use their power and resources to meet their fair share of responsibility and their moral and legal obligations. Rich countries and many middle-income countries that have the ability to do so are not transitioning away from fossil fuels fast enough to keep warming below 1.5°C, leading to more losses, damages and suffering. Rich countries are not providing the necessary finance to support developing countries to leapfrog to renewable energy.

“Rich countries have broken their US$100 billion climate finance promise and successfully blocked language at COP27 that would have required them to compensate for earlier shortfalls through increased climate finance in subsequent years. Climate finance is needed in the trillions for adaptation and mitigation. Given their responsibility for the climate crisis, rich countries at least could have provided a clear roadmap on how to deliver the US$600 billion they had promised between 2020 and 2025.

“We are also dismayed by the discussions to enhance the Gender Action Plan, which was at the heart of the UNFCCC processes for gender-responsive climate action. Gender was only marginally mentioned, if at all, in the climate talks’ decisions.

“The climate crisis is about inequality and injustice. Communities at the frontlines of the climate crisis are bearing the heaviest brunt of climate-induced disasters, in addition to multiple crises including conflict, loss of livelihoods, and economic shocks. World leaders must push political differences aside and put the needs of these communities first.”